Related Experiment Video
Updated: Jul 20, 2025
06:35
Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
Published on: March 29, 2024
707
The Anti-Aggregative Potential of Resolvin E1 on Human Platelets
Patrycja Szymańska1, Bogusława Luzak1, Katarzyna Miłowska2
1Department of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.
Molecules (Basel, Switzerland)
|July 29, 2023
Summary
Resolvin E1, an omega-3 fatty acid metabolite, inhibits platelet aggregation and activation via collagen receptors. This finding suggests potential applications for omega-3 PUFAs in preventing cardiovascular diseases.
Area of Science:
- Biochemistry
- Pharmacology
- Cardiovascular Research
Background:
- Omega-3 polyunsaturated fatty acids (PUFAs) possess known antiplatelet effects.
- The specific impact of resolvin E1 on platelet function via collagen receptors is poorly understood.
Purpose of the Study:
- To investigate resolvin E1's effect on collagen-induced platelet aggregation, activation, and reactivity.
- To explore resolvin E1's influence on platelet membrane fluidity and structure.
- To elucidate molecular mechanisms behind resolvin E1's anti-aggregative properties.
Main Methods:
- Assessing collagen-induced platelet aggregation in platelet-rich plasma, whole blood, and isolated platelets.
- Measuring P-selectin exposure on stimulated platelets.
- Evaluating platelet membrane fluidity and structure.
Main Results:
- Resolvin E1 significantly reduced collagen-induced platelet aggregation in platelet-rich plasma and isolated platelets, but not in whole blood.
- Resolvin E1 markedly decreased P-selectin exposure on collagen-stimulated platelets.
- Resolvin E1 maintained platelet membrane structure without increasing fluidity.
Conclusions:
- Resolvin E1 exhibits antiplatelet effects by inhibiting collagen-induced aggregation and activation.
- Further research is warranted to clarify the role of membrane fluidity and collagen receptors.
- Omega-3 PUFA metabolites like resolvin E1 represent a promising avenue for developing novel antiplatelet therapies for cardiovascular disease prevention.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
563
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563
01:22Formation of the Platelet Plug
6.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.7K
01:18Structure and Function of Platelets
1.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.2K
01:16Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K
01:17Intracellular Signaling Affects Focal Adhesions
2.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
753
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
753